FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2153928266> ?p ?o ?g. }

• W2153928266 abstract "Background Status epilepticus is a medical emergency associated with significant mortality and morbidity that requires immediate and effective treatment. Objectives (1) To determine whether a particular anticonvulsant is more effective or safer to use in status epilepticus compared to another and compared to placebo. (2) To delineate reasons for disagreement in the literature regarding recommended treatment regimens and to highlight areas for future research. Search methods For the latest update of this review, the following electronic databases were searched on 15/08/2013: the Cochrane Epilepsy Group's Specialized Register, CENTRAL The Cochrane Library July 2013, Issue 7, and MEDLINE (Ovid) 1946 to 15/08/2013. Selection criteria Randomised controlled trials of participants with premonitory, early, established or refractory status epilepticus using a truly random or quasi‐random allocation of treatments were included. Data collection and analysis Two review authors independently selected trials for inclusion, assessed trial quality and extracted data. Main results Eighteen studies with 2755 participants were included. Few studies used the same interventions. Intravenous diazepam was better than placebo in reducing the risk of non‐cessation of seizures (risk ratio (RR) 0.73, 95% confidence interval (CI) 0.57 to 0.92), requirement for ventilatory support (RR 0.39, 95% CI 0.16 to 0.94), or continuation of status epilepticus requiring use of a different drug or general anaesthesia (RR 0.73, 95% CI 0.57 to 0.92). Intravenous lorazepam was better than placebo for risk of non‐cessation of seizures (RR 0.52, 95% CI 0.38 to 0.71) and for risk of continuation of status epilepticus requiring a different drug or general anaesthesia (RR 0.52, 95% CI 0.38 to 0.71). Intravenous lorazepam was better than intravenous diazepam for reducing the risk of non‐cessation of seizures (RR 0.64, 95% CI 0.45 to 0.90) and had a lower risk for continuation of status epilepticus requiring a different drug or general anaesthesia (RR 0.63, 95% CI 0.45 to 0.88). Intravenous lorazepam was better than intravenous phenytoin for risk of non‐cessation of seizures (RR 0.62, 95% CI 0.45 to 0.86). Diazepam gel was better than placebo gel in reducing the risk of non‐cessation of seizures (RR 0.43 95% CI 0.30 to 0.62) For pre‐hospital treatment, intramuscular midazolam is at least as effective as (probably more effective than) intravenous lorazepam in control of seizures (RR1.16, 95% CI 1.06 to 1.27) and frequency of hospitalisation (RR 0.88, 95% CI 0.79 to 0.97) or intensive care admissions (RR 0.79, 95% CI 0.65 to 0.96). It was uncertain whether Intravenous valproate was better than intravenous phenytoin in reducing risk of non‐cessation of seizures (RR 0.75, 95% CI 0.28 to 2.00). Both levetiracetam and lorazepam were equally effective in aborting seizures (RR 0.97, 95% CI 0.44 to 2.13). Results for other comparisons of anticonvulsant therapies were uncertain due to single studies with few participants. The body of randomised evidence to guide clinical decisions is small. It was uncertain whether any anticonvulsant therapy was better than another in terms of adverse effects, due to few studies and participants identified. The quality of the evidence from the included studies is not strong but appears acceptable. We were unable to make judgements for risk of bias domains incomplete outcome reporting (attrition bias) and selective outcome reporting (selection bias) due to unclear reporting by the study authors. Authors' conclusions Intravenous lorazepam is better than intravenous diazepam or intravenous phenytoin alone for cessation of seizures. Intravenous lorazepam also carries a lower risk of continuation of status epilepticus requiring a different drug or general anaesthesia compared with intravenous diazepam. Both intravenous lorazepam and diazepam are better than placebo for the same outcomes. For pre hospital management, midazolam IM seemed more effective than lorazepam IV for cessation of seizures, frequency of hospitalisation and ICU admissions however,it was unclear whether the risk of recurrence of seizures differed between treatments. The results of other comparisons of anticonvulsant therapies versus each other were also uncertain. Universally accepted definitions of premonitory, early, established and refractory status epilepticus are required. Diazepam gel was better than placebo gel in reducing the risk of non‐cessation of seizures. Results for other comparisons of anticonvulsant therapies were uncertain due to single studies with few participants." @default.
• W2153928266 created "2016-06-24" @default.
• W2153928266 creator A5016360127 @default.
• W2153928266 creator A5052008114 @default.
• W2153928266 creator A5056679184 @default.
• W2153928266 creator A5084370003 @default.
• W2153928266 date "2014-09-10" @default.
• W2153928266 modified "2023-10-18" @default.
• W2153928266 title "Anticonvulsant therapy for status epilepticus" @default.
• W2153928266 cites W1492947450 @default.
• W2153928266 cites W1543435601 @default.
• W2153928266 cites W1978680513 @default.
• W2153928266 cites W1988646373 @default.
• W2153928266 cites W1995803117 @default.
• W2153928266 cites W2021360813 @default.
• W2153928266 cites W2034603635 @default.
• W2153928266 cites W2036467957 @default.
• W2153928266 cites W2045765644 @default.
• W2153928266 cites W2063899003 @default.
• W2153928266 cites W2071460026 @default.
• W2153928266 cites W2086981442 @default.
• W2153928266 cites W2092013975 @default.
• W2153928266 cites W2108055889 @default.
• W2153928266 cites W2108754014 @default.
• W2153928266 cites W2121665018 @default.
• W2153928266 cites W2125448218 @default.
• W2153928266 cites W2146482634 @default.
• W2153928266 cites W2149565580 @default.
• W2153928266 cites W2151359410 @default.
• W2153928266 cites W2473082783 @default.
• W2153928266 cites W4246162996 @default.
• W2153928266 cites W4250028527 @default.
• W2153928266 cites W4251639863 @default.
• W2153928266 cites W4319308490 @default.
• W2153928266 cites W4366956079 @default.
• W2153928266 doi "https://doi.org/10.1002/14651858.cd003723.pub3" @default.
• W2153928266 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7154380" @default.
• W2153928266 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25207925" @default.
• W2153928266 hasPublicationYear "2014" @default.
• W2153928266 type Work @default.
• W2153928266 sameAs 2153928266 @default.
• W2153928266 citedByCount "92" @default.
• W2153928266 countsByYear W21539282662012 @default.
• W2153928266 countsByYear W21539282662013 @default.
• W2153928266 countsByYear W21539282662014 @default.
• W2153928266 countsByYear W21539282662015 @default.
• W2153928266 countsByYear W21539282662016 @default.
• W2153928266 countsByYear W21539282662017 @default.
• W2153928266 countsByYear W21539282662018 @default.
• W2153928266 countsByYear W21539282662019 @default.
• W2153928266 countsByYear W21539282662020 @default.
• W2153928266 countsByYear W21539282662021 @default.
• W2153928266 countsByYear W21539282662022 @default.
• W2153928266 countsByYear W21539282662023 @default.
• W2153928266 crossrefType "journal-article" @default.
• W2153928266 hasAuthorship W2153928266A5016360127 @default.
• W2153928266 hasAuthorship W2153928266A5052008114 @default.
• W2153928266 hasAuthorship W2153928266A5056679184 @default.
• W2153928266 hasAuthorship W2153928266A5084370003 @default.
• W2153928266 hasBestOaLocation W21539282662 @default.
• W2153928266 hasConcept C118552586 @default.
• W2153928266 hasConcept C126322002 @default.
• W2153928266 hasConcept C142724271 @default.
• W2153928266 hasConcept C168563851 @default.
• W2153928266 hasConcept C177713679 @default.
• W2153928266 hasConcept C204787440 @default.
• W2153928266 hasConcept C27081682 @default.
• W2153928266 hasConcept C2776478404 @default.
• W2153928266 hasConcept C2777341932 @default.
• W2153928266 hasConcept C2778186239 @default.
• W2153928266 hasConcept C2779706987 @default.
• W2153928266 hasConcept C42219234 @default.
• W2153928266 hasConcept C44249647 @default.
• W2153928266 hasConcept C71924100 @default.
• W2153928266 hasConcept C82789193 @default.
• W2153928266 hasConceptScore W2153928266C118552586 @default.
• W2153928266 hasConceptScore W2153928266C126322002 @default.
• W2153928266 hasConceptScore W2153928266C142724271 @default.
• W2153928266 hasConceptScore W2153928266C168563851 @default.
• W2153928266 hasConceptScore W2153928266C177713679 @default.
• W2153928266 hasConceptScore W2153928266C204787440 @default.
• W2153928266 hasConceptScore W2153928266C27081682 @default.
• W2153928266 hasConceptScore W2153928266C2776478404 @default.
• W2153928266 hasConceptScore W2153928266C2777341932 @default.
• W2153928266 hasConceptScore W2153928266C2778186239 @default.
• W2153928266 hasConceptScore W2153928266C2779706987 @default.
• W2153928266 hasConceptScore W2153928266C42219234 @default.
• W2153928266 hasConceptScore W2153928266C44249647 @default.
• W2153928266 hasConceptScore W2153928266C71924100 @default.
• W2153928266 hasConceptScore W2153928266C82789193 @default.
• W2153928266 hasIssue "9" @default.
• W2153928266 hasLocation W21539282661 @default.
• W2153928266 hasLocation W21539282662 @default.
• W2153928266 hasLocation W21539282663 @default.
• W2153928266 hasLocation W21539282664 @default.
• W2153928266 hasOpenAccess W2153928266 @default.
• W2153928266 hasPrimaryLocation W21539282661 @default.
• W2153928266 hasRelatedWork W1995679204 @default.
• W2153928266 hasRelatedWork W2044020083 @default.
• W2153928266 hasRelatedWork W2086537853 @default.

• next